

Beth H Shaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3482471/publications.pdf>

Version: 2024-02-01

212
papers

7,522
citations

81839

39
h-index

60583

81
g-index

228
all docs

228
docs citations

228
times ranked

8519
citing authors

#	ARTICLE	IF	CITATIONS
19	The Terminal Ileum Is Affected in Patients With Lymphocytic or Collagenous Colitis. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1484-1492.	2.1	97
20	Pathophysiology of Early Trauma-Induced Coagulopathy: Emerging Evidence for Hemodilution and Coagulation Factor Depletion. <i>Journal of Trauma</i> , 2011, 70, 1401-1407.	2.3	90
21	A comparison of adverse reaction rates for <scp>PASâ€™C</scp> versus plasma platelet units. <i>Transfusion</i> , 2014, 54, 1927-1934.	0.8	86
22	Virome Analysis of Transfusion Recipients Reveals a Novel Human Virus That Shares Genomic Features with Hepaciviruses and Pegiviruses. <i>MBio</i> , 2015, 6, e01466-15.	1.8	80
23	Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion. <i>Journal of Clinical Investigation</i> , 2020, 130, 2270-2285.	3.9	69
24	The new approach to assignment of ASFA categoriesâ€™Introduction to the fourth special issue: Clinical applications of therapeutic apheresis. <i>Journal of Clinical Apheresis</i> , 2007, 22, 96-105.	0.7	65
25	Blood Donation and Blood Transfusion: Special Considerations for African Americans. <i>Transfusion Medicine Reviews</i> , 2008, 22, 202-214.	0.9	61
26	Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization?. <i>Transfusion</i> , 2009, 49, 1070-1075.	0.8	60
27	First cases of Zika virusâ€™infected US blood donors outside states with areas of active transmission. <i>Transfusion</i> , 2017, 57, 770-778.	0.8	59
28	Minority donation in the United States: challenges and needs. <i>Current Opinion in Hematology</i> , 2010, 17, 544-549.	1.2	56
29	Minority and foreignâ€™born representation among US blood donors: demographics and donation frequency for 2006. <i>Transfusion</i> , 2009, 49, 2221-2228.	0.8	53
30	Red Blood Cell Alloimmunization Mitigation Strategies. <i>Transfusion Medicine Reviews</i> , 2014, 28, 137-144.	0.9	53
31	Demographic Patterns of Blood Donors and Donations in a Large Metropolitan Area. <i>Journal of the National Medical Association</i> , 2011, 103, 351-357.	0.6	52
32	Development of common metrics for donation attitude, subjective norm, perceived behavioral control, and intention for the blood donation context. <i>Transfusion</i> , 2014, 54, 839-847.	0.8	51
33	Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study. <i>Transfusion</i> , 2016, 56, 1965-1973.	0.8	51
34	Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. <i>Transfusion</i> , 2015, 55, 1098-1107.	0.8	49
35	Motivators and barriers to blood donation in African American college students. <i>Transfusion and Apheresis Science</i> , 2009, 41, 191-197.	0.5	48
36	Racial Differences in Motivators and Barriers to Blood Donation Among Blood Donors. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1444-1447.	1.2	46

#	ARTICLE	IF	CITATIONS
37	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Medicine, 2021, 18, e1003872.	3.9	43
38	Early Predictors of Massive Transfusion in Patients Sustaining Torso Gunshot Wounds in a Civilian Level I Trauma Center. Journal of Trauma, 2010, 68, 298-304.	2.3	42
39	Zika Virus and the Blood Supply: What Do We Know?. Transfusion Medicine Reviews, 2017, 31, 1-10.	0.9	42
40	Outcomes after Massive Transfusion in Nontrauma Patients in the Era of Damage Control Resuscitation. American Surgeon, 2012, 78, 679-684.	0.4	41
41	Early trauma induced coagulopathy (ETIC): Prevalence across the injury spectrum. Injury, 2014, 45, 910-915.	0.7	40
42	COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion, 2021, 61, 1313-1323.	0.8	40
43	How did we rapidly implement a convalescent plasma program?. Transfusion, 2020, 60, 1348-1355.	0.8	40
44	Base deficit as a marker of survival after traumatic injury. Journal of Trauma, 2012, 72, 844-851.	2.3	38
45	The Blood Donor Identity Survey: a multidimensional measure of blood donor motivations. Transfusion, 2014, 54, 2098-2105.	0.8	38
46	Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 499.	0.7	38
47	Transfusion-transmitted and community-acquired babesiosis in New York, 2004 to 2015. Transfusion, 2018, 58, 660-668.	0.8	37
48	Sociodemographic and behavioral characteristics associated with blood donation in the United States: a population-based study. Transfusion, 2019, 59, 2899-2907.	0.8	37
49	Policies and Procedures Related to Testing for Weak D Phenotypes and Administration of Rh Immune Globulin: Results and Recommendations Related to Supplemental Questions in the Comprehensive Transfusion Medicine Survey of the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2014, 138, 620-625.	1.2	35
50	Evaluating a program to increase blood donation among racial and ethnic minority communities in New York City. Transfusion, 2014, 54, 3061-3067.	0.8	34
51	Trends in US minority red blood cell unit donations. Transfusion, 2017, 57, 1226-1234.	0.8	34
52	Impact of Uniform Methods on Interlaboratory Antibody Titration Variability: Antibody Titration and Uniform Methods. Archives of Pathology and Laboratory Medicine, 2017, 141, 131-138.	1.2	34
53	Survey of Irradiation Practice for the Prevention of Transfusion-Associated Graft-versus-Host Disease. Archives of Pathology and Laboratory Medicine, 2016, 140, 1092-1097.	1.2	31
54	COVID-19 convalescent plasma. Blood, 2022, 140, 196-207.	0.6	31

#	ARTICLE	IF	CITATIONS
55	Sequential clinical and histopathological changes in collagenous and lymphocytic colitis over time. <i>Modern Pathology</i> , 2004, 17, 395-401.	2.9	30
56	Uncrossmatched blood transfusions for trauma patients in the emergency department: incidence, outcomes and recommendations. <i>Canadian Journal of Surgery</i> , 2011, 54, 111-115.	0.5	29
57	Blood donations motivators and barriers: A descriptive study of African American and white voters. <i>Transfusion and Apheresis Science</i> , 2013, 48, 87-93.	0.5	29
58	The impact of a massive transfusion protocol (1:1:1) on major hepatic injuries: Does it increase abdominal wall closure rates?. <i>Canadian Journal of Surgery</i> , 2013, 56, E128-E134.	0.5	27
59	Category IV indications for therapeutic apheresis—ASFA fourth special issue. <i>Journal of Clinical Apheresis</i> , 2007, 22, 176-180.	0.7	26
60	Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. <i>Journal of Clinical Apheresis</i> , 2009, 24, 115-119.	0.7	25
61	A brief motivational interview with action and coping planning components enhances motivational autonomy among volunteer blood donors. <i>Transfusion</i> , 2016, 56, 1636-1644.	0.8	25
62	Trends in age and red blood cell donation habits among several racial/ethnic minority groups in the United States. <i>Transfusion</i> , 2017, 57, 1644-1655.	0.8	25
63	Ten years of TRALI mitigation: measuring our progress. <i>Transfusion</i> , 2019, 59, 2567-2574.	0.8	25
64	Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. <i>Transfusion</i> , 2019, 59, 1723-1733.	0.8	25
65	Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2008, 83, 212-217.	2.0	24
66	Demographic differences in estimated blood donor eligibility prevalence in the United States. <i>Transfusion</i> , 2012, 52, 1050-1061.	0.8	24
67	Determination of human platelet antigen typing by molecular methods: Importance in diagnosis and early treatment of neonatal alloimmune thrombocytopenia. <i>American Journal of Hematology</i> , 2012, 87, 525-528.	2.0	24
68	Contribution of attitudinal factors to blood donation in African American church attendees. <i>Transfusion</i> , 2011, 51, 158-165.	0.8	23
69	Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. <i>Blood</i> , 2014, 124, 1868-1872.	0.6	22
70	Reexamination of the chromium-51 labeled posttransfusion red blood cell recovery method. <i>Transfusion</i> , 2019, 59, 2264-2275.	0.8	21
71	Earlier the better: convalescent plasma. <i>Blood</i> , 2020, 136, 652-654.	0.6	21
72	<i>The Effects of Protocolized Use of Recombinant Factor VIIa Within a Massive Transfusion Protocol in a Civilian Level I Trauma Center</i> . <i>American Surgeon</i> , 2011, 77, 1043-1049.	0.4	20

#	ARTICLE	IF	CITATIONS
73	Measuring the processes of change for increasing blood donation in black adults. <i>Transfusion</i> , 2013, 53, 1280-1290.	0.8	19
74	Motivations for donating and attitudes toward screening policies in US blood donors with viral infection. <i>Transfusion</i> , 2016, 56, 2013-2020.	0.8	19
75	Applying self-determination theory to the blood donation context: The blood donor competence, autonomy, and relatedness enhancement (Blood Donor CARE) trial. <i>Contemporary Clinical Trials</i> , 2017, 53, 44-51.	0.8	19
76	Recent viral infection in US blood donors and health-related quality of life (HRQOL). <i>Quality of Life Research</i> , 2017, 26, 349-357.	1.5	19
77	Livers from Patients with Apolipoprotein A-I Amyloidosis Are Not Suitable as "Domino" Donors. <i>Modern Pathology</i> , 2001, 14, 577-580.	2.9	18
78	Residual risk of D alloimmunization: is it time to feel safe about platelets from D+ donors?. <i>Transfusion</i> , 2011, 51, 1132-1135.	0.8	17
79	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. <i>Transfusion</i> , 2021, 61, 78-93.	0.8	17
80	Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1705-1711.	1.2	16
81	Correlation of West Nile Virus Incidence in Donated Blood with West Nile Neuroinvasive Disease Rates, United States, 2010-2012. <i>Emerging Infectious Diseases</i> , 2017, 23, 212-219.	2.0	16
82	Age- and sex-dependent changes in levels of circulating brain-enriched microRNAs during normal aging. <i>Aging</i> , 2018, 10, 3017-3041.	1.4	16
83	Seasonal variability is not observed in the rates of high anti-A and anti-B titers in plasma, apheresis platelet, and whole blood units tested by different methods. <i>Transfusion</i> , 2019, 59, 762-767.	0.8	16
84	Perioperative Transfusions and Venous Thromboembolism. <i>Pediatrics</i> , 2020, 145, .	1.0	16
85	The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. <i>American Surgeon</i> , 2011, 77, 1043-9.	0.4	16
86	Outcomes after massive transfusion in nontrauma patients in the era of damage control resuscitation. <i>American Surgeon</i> , 2012, 78, 679-84.	0.4	16
87	Critical evaluation of informed consent forms for adult and minor aged whole blood donation used by United States blood centers. <i>Transfusion</i> , 2009, 49, 1136-1145.	0.8	15
88	Evidence of relative iron deficiency in platelet and plasma apheresis donors correlates with donation frequency. <i>Journal of Clinical Apheresis</i> , 2016, 31, 551-558.	0.7	15
89	Not all red cell concentrate units are equivalent: international survey of processing and in vitro quality data. <i>Vox Sanguinis</i> , 2019, 114, 783-794.	0.7	14
90	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. <i>Frontiers in Microbiology</i> , 2019, 10, 29.	1.5	14

#	ARTICLE	IF	CITATIONS
91	Factors associated with red blood cell, platelet, and plasma transfusions among inpatient hospitalizations: a nationally representative study in the United States. <i>Transfusion</i> , 2019, 59, 500-507.	0.8	14
92	The impact of age and sex on first-time donor return behavior. <i>Transfusion</i> , 2020, 60, 84-93.	0.8	14
93	How we approach an apheresis request for a Category III, Category IV, or noncategorized indication. <i>Transfusion</i> , 2007, 47, 1963-1971.	0.8	13
94	Transfusion medicine as a profession: evolution over the past 50 years. <i>Transfusion</i> , 2010, 50, 2536-2541.	0.8	13
95	Massive transfusion. <i>Current Opinion in Hematology</i> , 2013, 20, 521-525.	1.2	13
96	The value of area-based analyses of donation patterns for recruitment strategies. <i>Transfusion</i> , 2014, 54, 3051-3060.	0.8	12
97	Detection of bacterial contamination in apheresis platelets: is apheresis technology a factor?. <i>Transfusion</i> , 2015, 55, 2113-2122.	0.8	12
98	West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. <i>Transfusion</i> , 2012, 52, 2664-2670.	0.8	11
99	Acceptability and Feasibility of a Culturally Tailored Internet-Delivered Intervention to Promote Blood Donation in Blacks. <i>Health Promotion Practice</i> , 2015, 16, 227-235.	0.9	11
100	A motivational interview promotes retention of blood donors with high internal motivation. <i>Transfusion</i> , 2017, 57, 2433-2439.	0.8	11
101	American Society for Apheresis Guidelines Support Use of Red Cell Exchange Transfusion for Severe Malaria With High Parasitemia. <i>Clinical Infectious Diseases</i> , 2014, 58, 302-303.	2.9	10
102	How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures. <i>Transfusion</i> , 2014, 54, 17-25.	0.8	10
103	Bye-bye TRALL: by understanding and innovation. <i>Blood</i> , 2014, 123, 3374-3376.	0.6	10
104	Emerging Infections and Blood Safety in the 21st Century. <i>Annals of Internal Medicine</i> , 2016, 165, 57.	2.0	10
105	Perception of low-titer group A plasma and potential barriers to using this product: A blood center's experience serving community and academic hospitals. <i>Transfusion and Apheresis Science</i> , 2016, 55, 141-145.	0.5	10
106	Immune regulation of sickle cell alloimmunization. <i>ISBT Science Series</i> , 2017, 12, 248-253.	1.1	10
107	Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions. <i>Blood Advances</i> , 2017, 1, 1142-1147.	2.5	10
108	How do we manage blood donors and recipients after a positive Zika screening result?. <i>Transfusion</i> , 2017, 57, 2077-2083.	0.8	9

#	ARTICLE	IF	CITATIONS
109	An automated motivational interview promotes donation intention and self-efficacy among experienced whole blood donors. <i>Transfusion</i> , 2019, 59, 2876-2884.	0.8	9
110	A randomized controlled trial of a tablet-based intervention to address predonation fears among high school donors. <i>Transfusion</i> , 2020, 60, 1450-1453.	0.8	9
111	Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors. <i>Vox Sanguinis</i> , 2020, 115, 703-711.	0.7	9
112	Transfusion Transmitted Diseases. , 2009, , 361-371.		8
113	Cardiovascular disease risk assessment and prevention in blood donors. <i>Transfusion</i> , 2012, 52, 2174-2182.	0.8	8
114	Evaluating the Role of Blood Collection Centers in Public Health: A Status Report. <i>Transfusion Medicine Reviews</i> , 2012, 26, 58-67.	0.9	8
115	The Use of Platelet Antibody Testing at a Tertiary Medical Center.. <i>Blood</i> , 2004, 104, 3631-3631.	0.6	8
116	Results from the blood donor competence, autonomy, and relatedness enhancement (blood donor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	7
117	Impact of predictive scoring model and e-mail messages on African American blood donors. <i>Transfusion</i> , 2017, 57, 1515-1521.	0.8	6
118	Frequency of rare, serious donor reactions: International perspective. <i>Transfusion</i> , 2021, 61, 1780-1788.	0.8	6
119	Donor Iron Deficiency Study (DIDS): protocol of a study to test whether iron deficiency in blood donors affects red blood cell recovery after transfusion. <i>Blood Transfusion</i> , 2019, 17, 274-280.	0.3	6
120	Giving TRALI the one-two punch. <i>Blood</i> , 2012, 119, 1620-1621.	0.6	5
121	Perinatal Transfusion Medicine. , 2013, , 307-315.		5
122	Risk-based decision making: a good start to aiding US blood policy decisions?. <i>Transfusion</i> , 2018, 58, 1827-1830.	0.8	5
123	Remunerating donors to ensure a safe and available blood supply. <i>Transfusion</i> , 2020, 60, S134-S137.	0.8	5
124	Screening of blood donors for sickle cell trait using a DNA -based approach: Frequency in a multiethnic donor population. <i>Transfusion</i> , 2021, 61, 2008-2013.	0.8	5
125	Fear is associated with attrition of first-time whole blood donors: A longitudinal examination of donor confidence and attitude as potential mediators. <i>Transfusion</i> , 2021, 61, 3372-3380.	0.8	5
126	Blood donor eligibility criteria for medical conditions: A <sc>BEST</sc> collaborative study. <i>Vox Sanguinis</i> , 2022, 117, 929-936.	0.7	5

#	ARTICLE	IF	CITATIONS
127	The integration of high-throughput testing of blood donors for cardiovascular disease risk assessment and prevention. <i>Transfusion and Apheresis Science</i> , 2013, 49, 263-267.	0.5	4
128	Patient Blood Management. <i>JAMA Surgery</i> , 2013, 148, 491.	2.2	4
129	Apheresis to Mitigate Atherosclerotic Vascular Disease. <i>American Journal of Hypertension</i> , 2018, 31, 945-949.	1.0	4
130	Examination of the relationship between iron status and cognitive function among healthy young women with and without a recent history of blood donation. <i>Transfusion</i> , 2020, 60, 2886-2895.	0.8	4
131	Use of a rapid electronic survey methodology to estimate blood donors' potential exposure to emerging infectious diseases: Application of a statistically representative sampling methodology to assess risk in US blood centers. <i>Transfusion</i> , 2020, 60, 1987-1997.	0.8	4
132	The Development of a Social Networking-Based Relatedness Intervention Among Young, First-Time Blood Donors: Pilot Study. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e44.	1.2	4
133	Promoting awareness of donation-related iron depletion among high risk blood donors. <i>Transfusion</i> , 2021, 61, 3353-3360.	0.8	4
134	Comparative changes of preoperative autologous transfusions and perioperative cell salvage in the United States. <i>Transfusion</i> , 2020, 60, 2260-2271.	0.8	3
135	Blood transfusions in gunshot-wound-related emergency department visits and hospitalizations in the United States. <i>Transfusion</i> , 2021, 61, 2277-2289.	0.8	3
136	Warming Up to Cold-stored Platelets. <i>Anesthesiology</i> , 2020, 133, 1161-1163.	1.3	3
137	Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage. <i>Transfusion</i> , 2022, 62, 1619-1629.	0.8	3
138	ABO and H Blood Group System. , 2013, , 149-156.		2
139	Cryoprecipitate and Fibrinogen Concentrates. , 2013, , 227-230.		2
140	Adverse Donor Reactions. , 2013, , 53-59.		2
141	Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 2018, 58, 1065-1075.	0.8	2
142	Red blood cells: beyond the transfusion. <i>Blood</i> , 2019, 133, 2627-2628.	0.6	2
143	Zika virus and its implications on cord blood banking and transplantation. <i>Transfusion</i> , 2020, 60, 889-891.	0.8	2
144	Therapeutic Thrombocytapheresis. , 2009, , 403.		1

#	ARTICLE	IF	CITATIONS
145	Bacterial Detection Methods. , 2009, , 83-86.		1
146	Pretransfusion Testing. , 2009, , 93-101.		1
147	MNS and Duffy Blood Group Systems. , 2009, , 133-137.		1
148	Therapeutic Plasma Exchange. , 2009, , 383-397.		1
149	Autoimmune Hemolytic Anemias. , 2009, , 251-258.		1
150	Therapeutic Leukapheresis. , 2009, , 405-406.		1
151	Rh and RhAG Blood Group Systems. , 2013, , 157-162.		1
152	Overview of Infectious Disease Testing. , 2013, , 73-78.		1
153	Massive Transfusion. , 2013, , 367-372.		1
154	Current patterns of use in therapeutic apheresis: a metropolitan center experience. Transfusion, 2014, 54, 1899-1900.	0.8	1
155	Transfusion of Plasma and Plasma Derivatives. , 2018, , 1744-1758.		1
156	Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion, 2019, 59, 2733-2748.	0.8	1
157	Catch those antibodies before they fall. Blood, 2020, 136, 2489-2490.	0.6	1
158	Transfusion-Associated Graft-Versus-Host Disease and Microchimerism. , 0, , 107-116.		1
159	The Role of the Transfusion Service Physician. , 2009, , 87-92.		1
160	Cryoprecipitate. , 2009, , 175-178.		1
161	Frozen Blood Products. , 2009, , 223-225.		1
162	Allergic, Anaphylactoid and Anaphylactic Reactions. , 2009, , 311-315.		1

#	ARTICLE	IF	CITATIONS
163	Bacterial Detection Methods. , 2013, , 103-107.		1
164	A Pilot Trial To Assess College Studentâ€™s Willingness To Donate Blood.. Blood, 2007, 110, 4029-4029.	0.6	1
165	Donor Availability for Extended Phenotype Matching for Transfusion in Thalassemia and Sickle Cell Disease.. Blood, 2012, 120, 2287-2287.	0.6	1
166	Transfusion Practices and Infections At Four Level III Neonatal Intensive Care Units. Blood, 2013, 122, 3657-3657.	0.6	1
167	Perinatal Transfusion Medicine. , 2009, , 241-249.		1
168	Evidence Of Relative Iron Deficiency in Apheresis Platelet Donors Correlates With Donation Frequency. Blood, 2013, 122, 1155-1155.	0.6	1
169	Blood Management: Conservation, Salvage, and Alternatives to Allogeneic Transfusion. , 2007, , 419-434.		0
170	Lewis, I and P Blood Group Systems. , 2009, , 139-144.		0
171	Albumin and Related Products. , 2009, , 185-191.		0
172	Antibody Identification. , 2009, , 103-110.		0
173	LDL Pheresis. , 2009, , 411.		0
174	Transfusion Associated Graft Versus Host Disease. , 2009, , 345-352.		0
175	Human Immunoglobulin Preparations. , 2009, , 193-203.		0
176	Direct Antiglobulin Test. , 2009, , 111-114.		0
177	Kell and Kidd Blood Group Systems. , 2009, , 129-132.		0
178	Other Blood Group Systems, Collections and Antigens. , 2009, , 145-149.		0
179	Rh Blood Group System. , 2009, , 123-127.		0
180	Lewis, I, P1PK and GLOB Blood Group Systems. , 2013, , 171-176.		0

#	ARTICLE	IF	CITATIONS
181	Iron Overload. , 2013, , 449-451.		0
182	Kell and Kidd Blood Group Systems. , 2013, , 163-166.		0
183	Other Blood Group Systems, Collections, and Series. , 2013, , 177-183.		0
184	Human Immunoglobulin Preparations. , 2013, , 243-254.		0
185	Rh Immune Globulin. , 2013, , 255-258.		0
186	MNS and Duffy Blood Group Systems. , 2013, , 167-170.		0
187	Serologic Testing of Donor Products. , 2013, , 69-72.		0
188	Blood transfusion: preoperative considerations and complications. , 0, , 252-264.		0
189	Human Blood Group Antigens and Antibodies. , 2018, , 1687-1701.		0
190	Infectious Complications of Blood Transfusion. , 2018, , 241-266.		0
191	Donor incentives improve cardiovascular disease risk profile and donation rates. Transfusion, 2019, 59, 250-258.	0.8	0
192	Commentary: Patient blood management in the era of coronavirus disease 2019“is anything really different?. JTCVS Open, 2021, 5, 97-98.	0.2	0
193	Platelet Products. , 2009, , 167-174.		0
194	Microchimerism. , 2009, , 353-355.		0
195	Irradiation of Blood Products. , 2009, , 209-214.		0
196	Washed Blood Products. , 2009, , 227-229.		0
197	Transfusion Management in Patients with Hemoglobinopathies. , 2009, , 259-267.		0
198	ABO and H Blood Group Systems. , 2009, , 115-122.		0

#	ARTICLE	IF	CITATIONS
199	Perioperative Blood Management. , 2009, , 293-301.		0
200	Immunoadsorption. , 2009, , 413-414.		0
201	Therapeutic Erythrocytapheresis. , 2009, , 399-401.		0
202	Rh Immune Globulin. , 2009, , 205-208.		0
203	Metabolic, Hypotensive and Other Acute Reactions and Complications. , 2009, , 339-342.		0
204	Therapeutic Phlebotomy. , 2009, , 415-416.		0
205	Massive Transfusion. , 2009, , 287-291.		0
206	Overview of Therapeutic Apheresis. , 2009, , 373-382.		0
207	Effects of Pooling Multiple Red Blood Cell Units to Improve Storage. Blood, 2012, 120, 3437-3437.	0.6	0
208	Role of the Transfusion Service Physician. , 2013, , 109-115.		0
209	Metabolic, Hypotensive and Other Acute Reactions and Complications. , 2013, , 427-431.		0
210	Role of the Physician in the Blood Center. , 2013, , 31-35.		0
211	Therapeutic Phlebotomy. , 2013, , 529-531.		0
212	Low Dose Umbilical Cord Blood Transplant Results in Skewed Immune Cell Composition Which May Impact Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5672-5672.	0.6	0